NJ Justices Centralize Taxotere Hair-Loss Suits

Law360 (August 21, 2018, 3:45 PM EDT) -- An attorney representing women who claim they suffered permanent hair loss as a result of using the breast cancer drug Taxotere on Tuesday hailed the New Jersey Supreme Court’s decision to centralize the cases in the Garden State, where she says many patients took the medicine.

According to a notice made public Aug. 15, the justices in July granted multicounty litigation status to about 353 cases alleging Sanofi U.S. Services Inc., Sanofi-Aventis U.S. LLC, Sandoz Inc. and Actavis LLC failed to adequately warn consumers about the risk of permanent hair loss. The cases will be heard by Judge James F. Hyland...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS